LeadIQ logo
Learn more at LeadIQ.com

Insights

Loading spinner
Gathering insights about Cara Therapeutics…

Cara Therapeutics Tech Stack

Cara Therapeutics uses 8 technology products and services including SAP, Microsoft Outlook, Veeva Systems, and more. Explore Cara Therapeutics's tech stack below.

  • SAP
    Customer Relationship Management
  • Microsoft Outlook
    Email
  • Veeva Systems
    IT Infrastructure & Operations Management
  • JSON-LD
    Javascript Frameworks
  • dc.js
    Javascript Graphics
  • jQuery Migrate
    Javascript Libraries
  • Elementor
    Page Builders
  • X-XSS-Protection
    Security

Media & News

Cara Therapeutics's Email Address Formats

Cara Therapeutics uses at least 1 format(s):
Cara Therapeutics Email FormatsExamplePercentage
FLast@caratherapeutics.comJDoe@caratherapeutics.com
92%
First@caratherapeutics.comJohn@caratherapeutics.com
5%
First.Last@caratherapeutics.comJohn.Doe@caratherapeutics.com
2%
Last@caratherapeutics.comDoe@caratherapeutics.com
1%

Frequently Asked Questions

Where is Cara Therapeutics's headquarters located?

Minus sign iconPlus sign iconCara Therapeutics's main headquarters is located at 400 Atlantic Street Suite 500 Stamford, Connecticut 06901 United States. The company has employees across 3 continents, including North AmericaEuropeSouth America.

What is Cara Therapeutics's phone number?

Minus sign iconPlus sign icon You can contact Cara Therapeutics's main corporate office by phone at
+1-203-567-****
. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Cara Therapeutics's stock symbol?

Minus sign iconPlus sign iconCara Therapeutics is a publicly traded company; the company's stock symbol is BCAX.

What is Cara Therapeutics's official website and social media links?

Minus sign iconPlus sign iconCara Therapeutics's official website is caratherapeutics.com and has social profiles on LinkedInCrunchbase.

What is Cara Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign iconCara Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Cara Therapeutics have currently?

Minus sign iconPlus sign iconAs of February 2026, Cara Therapeutics has approximately 51 employees across 3 continents, including North AmericaEuropeSouth America. Key team members include Cfo: J. S.Chief Medical Officer: J. G.Chief Medical Officer: J. S.. Explore Cara Therapeutics's employee directory with LeadIQ.

What industry does Cara Therapeutics belong to?

Minus sign iconPlus sign iconCara Therapeutics operates in the Biotechnology Research industry.

What technology does Cara Therapeutics use?

Minus sign iconPlus sign iconCara Therapeutics's tech stack includes SAPMicrosoft OutlookVeeva SystemsJSON-LDdc.jsjQuery MigrateElementorX-XSS-Protection.

What is Cara Therapeutics's email format?

Minus sign iconPlus sign iconCara Therapeutics's email format typically follows the pattern of FLast@caratherapeutics.com. Find more Cara Therapeutics email formats with LeadIQ.

How much funding has Cara Therapeutics raised to date?

Minus sign iconPlus sign icon As of February 2026, Cara Therapeutics has raised $40M in funding. The last funding round occurred on Nov 02, 2023 for $40M.

When was Cara Therapeutics founded?

Minus sign iconPlus sign iconCara Therapeutics was founded in 2004.

Cara Therapeutics

Biotechnology ResearchConnecticut, United States51-200 Employees

Cara Therapeutics is a mid-sized biotechnology company based in Stamford, Connecticut, focused on developing treatments for pruritus. Its portfolio includes an oral formulation of difelikefalin for chronic pruritus associated with notalgia paresthetica, pursued in a Phase 2/3 program with topline dose-finding results expected in the third quarter of 2024. Additionally, the firm has developed an intravenous difelikefalin formulation that is approved for moderate-to-severe pruritus in adults undergoing hemodialysis due to advanced chronic kidney disease, with the IV product licensed worldwide.

As a development-stage player in the biotechnology research space, Cara operates with a focus on pruritus-related conditions and related therapies. In March 2025, Cara announced a merger with Tvardi Therapeutics, with completion expected in the first half of the year.

Section iconCompany Overview

Headquarters
400 Atlantic Street Suite 500 Stamford, Connecticut 06901 United States
Phone number
+1-203-567-****
Website
caratherapeutics.com
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
BCAX
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2004
Employees
51-200

Section iconMedia & News

Section iconFunding & Financials

  • $40M

    Cara Therapeutics has raised a total of $40M of funding over 10 rounds. Their latest funding round was raised on Nov 02, 2023 in the amount of $40M.

  • $10M$25M

    Cara Therapeutics's revenue is estimated to be in the range of $10M$25M

Section iconFunding & Financials

  • $40M

    Cara Therapeutics has raised a total of $40M of funding over 10 rounds. Their latest funding round was raised on Nov 02, 2023 in the amount of $40M.

  • $10M$25M

    Cara Therapeutics's revenue is estimated to be in the range of $10M$25M

Company Leadership

  • Stylized image of a person
    J. S.
    Cfo
    Phone icon
    Mobile Phone
  • Stylized image of a person
    J. G.
    Chief Medical Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    J. S.
    Chief Medical Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    S. C.
    Vice President Cmc Technical Operations
    Phone icon
    Mobile Phone
  • Stylized image of a person
    D. C.
    President &ceo
    Phone icon
    Mobile Phone

Employee Directory

  • Stylized image of a person
    C. M.
    Head Of Biometrics
    Phone icon
    Mobile Phone
  • Stylized image of a person
    D. H.
    Head Of Quality Assurance And Compliance
    Phone icon
    Mobile Phone
  • Stylized image of a person
    H. V.
    Vice President, Information Technology Operations
    Phone icon
    Mobile Phone
  • Stylized image of a person
    S. C.
    Vice President Cmc Technical Operations
    Phone icon
    Mobile Phone
  • Stylized image of a person
    Z. P.
    Associate Director, Drug Safety Pharmacovigilance
    Phone icon
    Mobile Phone

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.